Kodiak Sciences (KOD) Other Accumulated Expenses (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Other Accumulated Expenses came in at $2.0 million in Q1 2026, up 116.9% YoY from $917000.0 in Q1 2025, and up 55.27% on a QoQ basis from $1.3 million in Q4 2025.
Analysis
Kodiak Sciences (KOD) Other Accumulated Expenses (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Other Accumulated Expenses data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Other Accumulated Expenses rose 116.9% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 116.9% YoY) and the FY2025 annual result came in at $1.3 million, up 246.22% from the prior year.
- Other Accumulated Expenses rose to $2.0 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $3.0 million in Q2 2022 to a low of $343000.0 in Q3 2024.
- A 5-year average of $1.2 million and a median of $1.0 million in 2022 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses slumped 83.27% — and 2025, when it jumped 246.22%.
- Tracing KOD's Other Accumulated Expenses over 5 years: stood at $919000.0 in 2022, then decreased by 22.31% to $714000.0 in 2023, then tumbled by 48.18% to $370000.0 in 2024, then jumped by 246.22% to $1.3 million in 2025, then soared by 55.27% to $2.0 million in 2026.
- The last three Other Accumulated Expenses figures came in at $2.0 million (Q1 2026), $1.3 million (Q4 2025), and $496000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | 1.99 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 496,000.00 |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 917,000.00 |
| Dec 31, 2024 | 370,000.00 |
| Sep 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 456,000.00 |
| Mar 31, 2024 | 953,000.00 |
| Dec 31, 2023 | 714,000.00 |
| Sep 30, 2023 | 1.49 Mn |
| Jun 30, 2023 | 2.73 Mn |
| Mar 31, 2023 | 1.15 Mn |
| Dec 31, 2022 | 919,000.00 |
| Sep 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 2.96 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 715,000.00 |
| Sep 30, 2021 | 797,000.00 |